TABLE 1.

HIV tropisms predicted by the Geno2Pheno[454] typing tool, drug resistance mutations, and the corresponding drugs HIV-positive patients in this study have been exposed to previously or are currently taking^a

Patient	No. of yr infectedb	% CXCR4 tropic	Drug resistance mutation(s)	% sequences with mutation(s)c	Coverage depth at DR sited	Drugs taken by patient that may influence mutationse	Patient currently taking drugsb
108	>14	94.8	K103N	1.4	497	EFV, NVP	No
			G333E	99.4	664	3TC	No
113	20	0	M41L	23.2	283	D4T, ddI	No
			D67N	4.1	276	D4T, ddI	No
			K219Q	1.2	244	D4T	No
114	>10	4.1	D67N	2.4	403	TDF	No
			K219Q	2.7	333	None	N/A
115	9	7.1	K65R	1.3	73	3TC, FTC, TDF	Yes
			F77L	2.9	69	ZDV	No
116	1	0	K219Q	7.9	178	None	N/A
			G333E	36.1	242	None	N/A
121	9	0	L74I	74	231	None	N/A
			A98G	1.7	236	EFV	No
			K103N	95.9	224	EFV	No
			V108I	8.9	235	EFV	No
			M184V	98.9	294	3TC	No
			P225H	92.3	234	ZDV, 3TC	No
			G333E	100	346	ZDV, 3TC	No
Br1005	2	0	None
Br2026	4	0	None
Br1058	2	0	None
Br1009	<2 mo	0	D67N	1.3	798	None	N/A
Br1048	<1 mo	0	D67N	1.5	350	None	N/A
HXB2_1	N/A	100	None
HXB2_2	N/A	100	None

^aThe false-positive rate for predictions with the Geno2Pheno[454] typing tool was 1%.

^bN/A, not applicable.

^cBoldface type indicates that the background mutation was observed in the HBX2 vector control. Underlining indicates a low level of sequence coverage.

^dDR, drug resistance.

^eEFV, efavirenz; NVP, nevirapine; 3TC, lamivudine; D4T, stavudine; ddI, dideoxyinosine; TDF, tenofovir; FTC, emtricitabine; ZDV, zidovudine.